Summary of Study ST002390
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001537. The data can be accessed directly via it's Project DOI: 10.21228/M81B0N This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002390 |
| Study Title | The metabolomic resetting effect of DMXAA in cisplatin-induced injured mouse kidney |
| Study Summary | A single injection of cisplatin was used to induce AKI in mice. To assess the effect of DMXAA, the mice were injected intraperitoneally with DMXAA or vehicle one hour before cisplatin injection, repeated every 24 hours. The mice were euthanized 72 hours after cisplatin injection, and renal tissues were collected for MS analysis. |
| Institute | Children's Hospital of Nanjing Medical University |
| Last Name | Lu |
| First Name | Lingling |
| Address | Guangzhou Road 72, Nanjing, Jiangsu, 210000, China |
| lulingling89tara@163.com | |
| Phone | 0086-25-8311-7435 |
| Submit Date | 2022-12-05 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-03-03 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001537 |
| Project DOI: | doi: 10.21228/M81B0N |
| Project Title: | The metabolomic resetting effect of DMXAA in cisplatin-induced AKI |
| Project Type: | MS quantitative analysis |
| Project Summary: | Cisplatin-induced nephrotoxicity is the main adverse effect of cisplatin-based chemotherapy, which highly limits the clinical use of cisplatin. DMXAA, a flavonoid derivative as a known agonist of STING, has been served as a promising antivascular agent. Although cGAS-STING activation has been demonstrated to mediate cisplatin-induced AKI, the role of DMXAA in this condition is unclear. Here, we defined an unexpected and critical role of DMXAA in improving renal function, ameliorating renal tubular injury and cell apoptosis, suppressing inflammation in cisplatin-induced AKI. Moreover, we confirmed that DMXAA combated AKI in a STING-independent manner evidenced by its protection against AKI in STING knockout mice. Due to the established role of metabolic disorders in AKI, which could contribute to the injury and kidney recovery, we performed metabolomics using renal tissues from cisplatin-induced AKI mice with or without DMXAA treatment. Strikingly, the date revealed that DMXAA improved the metabolic disorders in kidneys of AKI mice, especially restored the tryptophan metabolism. |
| Institute: | Children's Hospital of Nanjing Medical University |
| Department: | Department of Nephrology, State Key Laboratory of Reproductive Medicine, |
| Laboratory: | Nanjing Key Lab of Pediatrics, Jiangsu Key Laboratory of Pediatrics |
| Last Name: | Lu |
| First Name: | Lingling |
| Address: | Guangzhou Road 72, Nanjing, Jiangsu, 210000, China |
| Email: | lulingling89tara@163.com |
| Phone: | 0086-25-8311-7435 |
